156 related articles for article (PubMed ID: 1131393)
1. Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite.
Struck RF; Kirk MC; Witt MH; Laster WR
Biomed Mass Spectrom; 1975 Feb; 2(1):46-52. PubMed ID: 1131393
[TBL] [Abstract][Full Text] [Related]
2. Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy.
Jardine I; Fenselau C; Appler M; Kan MN; Brundrett RB; Colvin M
Cancer Res; 1978 Feb; 38(2):408-15. PubMed ID: 620410
[TBL] [Abstract][Full Text] [Related]
3. The determination of cyclophosphamide and its metabolites in blood plasma as stable trifluoroacetyl derivatives by electron capture chemical ionization gas chromatography/mass spectrometry.
Momerency G; Van Cauwenberghe K; Slee PH; Van Oosterom AT; De Bruijn EA
Biol Mass Spectrom; 1994 Mar; 23(3):149-58. PubMed ID: 8148406
[TBL] [Abstract][Full Text] [Related]
4. Blood levels of alkylating metabolites of cyclophosphamide in the mouse after iv or oral administration.
Struck RF; Alberts DS
Cancer Treat Rep; 1984 May; 68(5):765-70. PubMed ID: 6722832
[TBL] [Abstract][Full Text] [Related]
5. Approaches to the pharmacokinetics of cyclophosphamide (NSC 26271): Quantitation of metabolites.
Jardine I; Brundrett R; Colvin M; Fenselau C
Cancer Treat Rep; 1976 Apr; 60(4):403-8. PubMed ID: 1277214
[TBL] [Abstract][Full Text] [Related]
6. Half-life of oxazaphosphorines in biological fluids.
Sladek NE; Powers JF; Grage GM
Drug Metab Dispos; 1984; 12(5):553-9. PubMed ID: 6149904
[TBL] [Abstract][Full Text] [Related]
7. Conversion of 4-hydroperoxycyclophosphamide and 4-hydroxycyclophosphamide to phosphoramide mustard and acrolein mediated by bifunctional catalysis.
Low JE; Borch RF; Sladek NE
Cancer Res; 1982 Mar; 42(3):830-7. PubMed ID: 7059981
[TBL] [Abstract][Full Text] [Related]
8. Alkylating properties of phosphoramide mustard.
Colvin M; Brundrett RB; Kan MN; Jardine I; Fenselau C
Cancer Res; 1976 Mar; 36(3):1121-6. PubMed ID: 1253171
[TBL] [Abstract][Full Text] [Related]
9. Identification and pharmacokinetics of cyclophosphamide (NSC-26271) metabolites in vivo.
Voelcker G; Wagner T; Hohorst HJ
Cancer Treat Rep; 1976 Apr; 60(4):415-22. PubMed ID: 1277216
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of deuterium-labeled analogs of cyclophosphamide and its metabolites.
Griggs LJ; Jarman M
J Med Chem; 1975 Nov; 18(11):1102-6. PubMed ID: 1177255
[TBL] [Abstract][Full Text] [Related]
11. The effect of cimetidine on cyclophosphamide metabolism in rabbits.
Anthony LB; Long QC; Struck RF; Hande KR
Cancer Chemother Pharmacol; 1990; 27(2):125-30. PubMed ID: 2249327
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of neutrophil chemotaxis by 4-hydroxycyclophosphamide.
Gilbert DN; Starr P; Eubanks N
Cancer Res; 1977 Feb; 37(2):456-9. PubMed ID: 832269
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of 4-hydroxycyclophosphamide and metabolites in the rat.
Hong PS; Srigritsanapol A; Chan KK
Drug Metab Dispos; 1991; 19(1):1-7. PubMed ID: 1673381
[TBL] [Abstract][Full Text] [Related]
14. Isolation and identification of a stabilized derivative of aldophosphamide, a major metabolite of cyclophosphamide.
Struck RF
Cancer Res; 1974 Nov; 34(11):2933-5. PubMed ID: 4417999
[No Abstract] [Full Text] [Related]
15. Binding of metabolites of cyclophosphamide to DNA in a rat liver microsomal system and in vivo in mice.
Hemminki K
Cancer Res; 1985 Sep; 45(9):4237-43. PubMed ID: 4028012
[TBL] [Abstract][Full Text] [Related]
16. Identification of aldophosphamide as a metabolite of cyclophosphamide in vitro and in vivo in humans.
Fenselau C; Kan MN; Rao SS; Myles A; Friedman OM; Colvin M
Cancer Res; 1977 Aug; 37(8 Pt 1):2538-43. PubMed ID: 872080
[TBL] [Abstract][Full Text] [Related]
17. Cyclophosphamide (NSC-26271)-related phosphoramide mustards- recent advances and historical perspective.
Friedman OM; Wodinsky I; Myles A
Cancer Treat Rep; 1976 Apr; 60(4):337-46. PubMed ID: 1277209
[TBL] [Abstract][Full Text] [Related]
18. Phenotypically deficient urinary elimination of carboxyphosphamide after cyclophosphamide administration to cancer patients.
Hadidi AH; Coulter CE; Idle JR
Cancer Res; 1988 Sep; 48(18):5167-71. PubMed ID: 3409242
[TBL] [Abstract][Full Text] [Related]
19. Identification and quantitation of alcophosphamide, a metabolite of cyclophosphamide, in the rat using chemical ionization mass spectrometry.
Hong PS; Chan KK
Biomed Environ Mass Spectrom; 1987 Apr; 14(4):167-72. PubMed ID: 2954602
[TBL] [Abstract][Full Text] [Related]
20. Individual variation in the activation and inactivation of metabolic pathways of cyclophosphamide.
Boddy AV; Furtun Y; Sardas S; Sardas O; Idle JR
J Natl Cancer Inst; 1992 Nov; 84(22):1744-8. PubMed ID: 1433359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
